Suppr超能文献

肌萎缩侧索硬化症:运动神经元的无声杀手。传统中药作为一种有效疗法。

ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy.

作者信息

Rai Anjali, Shukla Shivang, Gupta Ramesh Kumar, Mishra Anuradha

机构信息

Amity Institute of Pharmacy, Amity University, Lucknow, Uttar Pradesh, India.

出版信息

Curr Pharm Des. 2025;31(17):1328-1346. doi: 10.2174/0113816128329141241205063352.

Abstract

Amyotrophic lateral sclerosis (ALS), is a progressive neurodegenerative disease characterized by motor symptoms, and cognitive impairment. The complexity in treating ALS arises from genetic and environmental factors, contributing to the gradual decline of lower and upper motor neurons. The anticipated pharmaceutical market valuation for ALS is projected to reach $1,038.94 million by 2032. This projection underscores the escalating impact of ALS on global healthcare systems. ALS prevalence is expected to surge to 376,674 cases by 2040. In 2022, India ranked among the top 3 Asian-Pacific nations, while North America dominated the global ALS market. Ongoing investigations explore the potential of neuroprotective drugs like riluzole and edaravone in ALS treatment. Recently approved drugs, Relyvrio (sodium phenylbutyrate and taurursodiol) and Tofersen (Qalsody) have completed the trials, and others are currently undergoing extensive clinical trials. Continuous research and exploration of therapeutic avenues, including gene therapy and neuroprotective treatments, are imperative to address the challenges posed by ALS and other neurodegenerative diseases. Traditional Chinese medicine (TCM) approaches and clinical trials are being explored for treating ALS symptoms, targeting neuroinflammation, oxidative damage, and muscle weakness, showcasing the potential benefits of integrating traditional and modern approaches in ALS management.

摘要

肌萎缩侧索硬化症(ALS)是一种进行性神经退行性疾病,其特征为运动症状和认知障碍。治疗ALS的复杂性源于遗传和环境因素,这些因素导致上下运动神经元逐渐衰退。预计到2032年,ALS的药品市场估值将达到1.03894亿美元。这一预测凸显了ALS对全球医疗系统的影响不断升级。预计到2040年,ALS的患病率将激增至376,674例。2022年,印度在亚太国家中排名前三,而北美主导着全球ALS市场。正在进行的研究探索了利鲁唑和依达拉奉等神经保护药物在ALS治疗中的潜力。最近获批的药物Relyvrio(苯丁酸钠和牛磺熊去氧胆酸)和Tofersen(Qalsody)已完成试验,其他药物目前正在进行广泛的临床试验。持续开展对包括基因治疗和神经保护治疗在内的治疗途径的研究和探索,对于应对ALS和其他神经退行性疾病带来的挑战至关重要。正在探索采用传统中医方法和开展临床试验来治疗ALS症状,针对神经炎症、氧化损伤和肌肉无力,这显示了将传统与现代方法相结合用于ALS管理的潜在益处。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验